2024 | | Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial | 강석윤 |
2010 | | New drugs in hematological disorders | 박준성, 정성현 |
2018 | | OA10.05: An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09) | 이현우 |
2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
2020 | | Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia | 박준성 |
2015 | | Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |
2020 | | Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) | 안미선 |
2009 | | Outcome of Locally Advanced Esophageal Cancer Treated with Concurrent Chemo-radiotherapy | 강석윤, 강승희, 오영택, 전미선, 최진혁 |
2023 | | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | 정성현, 최윤석 |
1996 | | Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. | 최진혁 |
2022 | | Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 | 강석윤 |
2018 | | P1.15-14: Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study | 이현우, 정준호, 허재성 |
2023 | | p15INK4B is an alternative marker of senescent tumor cells in colorectal cancer | 김영화, 김장희, 박태준, 신준상, 이영경, 임수빈, 최용원 |
2018 | | P2.12-01: Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study | 최진혁 |
2019 | | Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial | 강석윤 |
1995 | | Patency of a small vessel prosthesis bonded to tissue plasminogen activator and iloprost. | 김효철 |
2012 | | Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases | 김보영, 김세혁, 김영배, 김장희, 신승수, 이기범, 이현우, 정선용, 한재호 |
2018 | | Patient's Cognitive Function and Attitudes towards Family Involvement in Cancer Treatment Decision Making: A Patient-Family Caregiver Dyadic Analysis | 이현우 |
2020 | | Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10) | 강석윤 |
2014 | | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. | 강석윤, 박준성, 안미선, 이현우, 정성현, 최용원, 최진혁 |